Cyprotex, the pharmaceuticals company specialising in the adverse effects of chemicals on living organisms, has signed a collaborative research agreement with US pharmaceuticals giant Pfizer.
The two parties will evaluate, further develop, and improve several of Cyprotex's proprietary offerings in the area of predictive toxicology.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction. Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients," said Dr Anthony Baxter, Cyprotex's Chief Executive Officer.
-
Norfolk or Norway? Holidays you can afford with different-sized pension potsMany people look forward to taking more holidays when they retire. But what sort of trips could your pension buy you? We look at the holidays to match different retirement incomes
-
Q&A: Issac Thong – new lead manager of Aberdeen Asian Income Fund
